Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: An open-label, single-dose, two-way crossover pharmacokinetic study in healthy caucasian and Japanese men

Clinical Drug Investigation

Volumn 31, Issue 10, 2011, Pages 735-743

  Warrington, Steve ^a   Nagakawa, Shunji ^b   Hounslow, Neil ^c  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^b KOWA COMPANY LTD   (Japan)

^c Kowa Research Europe   (United Kingdom)

Author keywords

Bioequivalence; Ethnic groups; HMG CoA reductase inhibitors; Hyperlipidaemia; Pitavastatin

Indexed keywords

DRUG METABOLITE; PITAVASTATIN; PITAVASTATIN LACTONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CAUCASIAN; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ETHNIC DIFFERENCE; ETHNIC GROUP; HEART RATE; HUMAN; HUMAN EXPERIMENT; JAPANESE; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; QUINOLINES; THERAPEUTIC EQUIVALENCY;

EID: 80052484231     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11592480-000000000-00000     Document Type: Article

References (16)

1. Hayashi T, Yokote K, Saito Y, et al. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother 2007; 8: 2315-27 (Pubitemid 350001592)
2. Ahmad H, Cheng-Lai A. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Cardiol Rev 2010; 18: 264-7
3. Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag 2009; 5: 921-36
4. Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO tablet): LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther 2008; 36: 709-31
5. Catapano AL. Pitavastatin: pharmacological profile from early phase studies. Atheroscler Suppl. 2010; 11: 3-7
6. Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and Western countries. Clin Pharmacol Ther 2010; 87: 714-20
7. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003; 43: 943-67 (Pubitemid 37022739)
8. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50 (Pubitemid 32385908)
9. Romaine SP, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010; 10: 1-11
10. Wen J, Xiong Y. OATP1B1 388AG polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 2010; 35: 99-104
11. Yang GP, Yuan H, Tang B, et al. Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol Sin 2010; 31: 382-6
12. Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr MedRes Opin 2009; 25: 2755-64
13. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008; 201: 345-52
14. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] study). J Am Coll Cardiol 2009; 54: 293-302
15. Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease: sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb 2010; 17: 601-9
16. Teramoto T, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 2009; 16: 654-61